Citius Oncology Inc.

CTOR | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.05

+$0.01 (+0.48%)

At close: Sep 22, 2026, 3:59 PM ET

$1.07

+$0.02 (+1.90%)

After-hours: Sep 22, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.48%

(1D)

Rating

Updated: Aug 31, 2026

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $98.1M

1D Range

1 1.12

52W Range

0.49 2.25

Valuation (TTM)

PE -2.17

PB 2.41

EV/EBITDA -2.11

Valuation (NTM)

Forward PE 13.26

Forward PEG 0.02

Price Target $6

Cash Flow

FCF Yield -20.3%

SBC Adj. FCF Yield -20.3%

SBC Impact N/A

Margins

Gross Margin 53.1%

Operating Margin -665.6%

FCF Margin -277.3%

Growth (CAGR)

Revenue 3Y | 5Y 150.0% | N/A

Dil EPS 3Y | 5Y 9.4% | N/A

FCF 3Y | 5Y -143.5% | N/A

Returns

ROA -41.1%

ROE -103.0%

ROIC -88.7%

Financial Health

Net Cash

$6.35M

Current Ratio 0.73

Interest Coverage -86.40

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigationa...

Sector Healthcare

Industry Medical - Pharmaceuticals

Employees 285

IPO Date Dec 7, 2022

Website www.citiusonc.com/overview/default.aspx

Fiscal Year n/a

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Dec 17, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+471.43%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞